Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRESCENDO: Beleodaq-CHOP or Folotyn-COP vs CHOP in Newly Diagnosed PTCL
NCT06072131Phase 3Active, not recruiting
- Sponsor
- Acrotech Biopharma Inc
- Start
- Oct 2023
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of belinostat, pralatrexate in peripheral T-cell lymphoma (PTCL), sponsored by Acrotech Biopharma Inc. Started Oct 2023; status: active, not recruiting.
02
Drugs
belinostatpralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06072131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072131.